2013³â 9¿ù 7ÀÏ Åä¿äÀÏ
Àå¼Ò ½êÄÚ
°ÀÇ ½ºÄÉÁì
2013³â °æ»ó³²µµ °³¿ø ³»°úÀÇ»çȸ Ãß°èÇмú ´ëȸ
ÀÓ»óÃÊÀ½ÆÄ ÇÐȸ °æ³²Áöȸ/
:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />
1. µî·Ï ¹× ºÎ½º °ü¶÷ 4-5
2. ÇãÇ÷¼º½ÉÁúȯÀÇ ÃֽŠÁö°ß 5.-5.30 ÇãÁ¤È£(°í½Å´ë)
3. ½ÉÃÊÀ½ÆÄ 5.30-6 ÃʽÉÀÚ°¡ ½ÉÃÊÀ½ÆÄ °Ë»çÇÒ ¶§ ÁÖÀÇÇÒ Á¡°ú artifacts Á¶°æÀÓ (°í½Å´ë)
4. ½ÉÃÊÀ½ÆÄ 6-6.30 Evaluation of Mitral & Aortic valve disease ¹ÚÁ¤¶û (°æ»ó´ë)
5. Àú³á ½ÉÆ÷Áö¾ö 1°ÀÇ DPP4 inhibitor comparison ±è¼öÁß(°æÈñÀÇ´ë) 6:30-7:00
6. Àú³á ½ÉÆ÷Áö¾ö 2°ÀÇ New Concept; Treatment of BPH-LUTS in ED Patients using tadalafil 5mg OAD ¹ÚÇöÁØ(ºÎ»êÀÇ´ë)7:00-7:30
7. coffee break time 7:30-7:40
8. °£ÃÊÀ½ÆÄ 7:40-8:10 Standardization & view points of upper abdominal ultrasonography Çѻ󼮱³¼ö´Ô (ÀÎÁ¦´ë)
9.Ãé´ãµµ ÃÊÀ½ÆÄ 8:10-8:40 ´ã³¶ ¹× Ãé´ãµµ º´º¯ ³õÄ¡Áö ¸»¾Æ¾ß ÇÒ ÃÊÀ½ÆÄ ¼Ò°ß? ÇØ¿î´ë ¹éº´¿ø ¹®¿µ¼ö (ÀÎÁ¦´ë)
10.º¹ºÎ 840:-9:10 ±Þ¼º Ãæ¼ö¿° ½±°Ô ã±â ¹× ±âŸ º¹ºÎ Áúȯ( °£ Ãé´ãµµ ÀÌ¿Ü) ±èÀϺÀ³»°ú
11 Q&A 9:10-9:30